Profile data is unavailable for this security.
About the company
Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Its lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. It is also expanding into solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. It focuses on integrating IL-12-TM technology into its solid tumor programs.
- Revenue in AUD (TTM)525.53k
- Net income in AUD-7.51m
- Incorporated1999
- Employees14.00
- LocationArovella Therapeutics LtdOsborne Park, U 12 L 1, 55 Howe StPERTH 3053AustraliaAUS
- Phone+61 39863-6472
- Fax+61 89443-8858
- Websitehttps://www.arovella.com/
